Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Authors
Schöffski, PSufliarsky, J
Gelderblom, H
Blay, J
Strauss, S
Stacchiotti, S
Rutkowski, P
Lindner, L
Leahy, Michael G
Italiano, A
Isambert, N
Debiec-Rychter, M
Sciot, R
Van Cann, T
Marréaud, S
Nzokirantevye, A
Collette, S
Wozniak, A
Affiliation
Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumIssue Date
2018-06
Metadata
Show full item recordAbstract
An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.Citation
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. 2018, 6(6): 431-441 Lancet Respir MedJournal
The Lancet Respiratory MedicineDOI
10.1016/S2213-2600(18)30116-4PubMed ID
29669701Type
ArticleLanguage
enISSN
2213-2619ae974a485f413a2113503eed53cd6c53
10.1016/S2213-2600(18)30116-4